MARKET

ROIV

ROIV

Roivant Sciences
NASDAQ
35.80
-0.33
-0.91%
After Hours: 35.17 -0.63 -1.76% 19:33 09/25 EDT
OPEN
35.98
PREV CLOSE
36.13
HIGH
36.19
LOW
35.52
VOLUME
6.76M
TURNOVER
--
52 WEEK HIGH
42.50
52 WEEK LOW
14.50
MARKET CAP
25.86B
P/E (TTM)
-91.9599
1D
5D
1M
3M
1Y
5Y
1D
Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)
TipRanks · 12h ago
Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback
TipRanks · 3d ago
Roivant's IMVT-1402 Shows Positive Trends In Lupus Skin Disease Study, But Misses Main Goal
NASDAQ · 3d ago
Immunovant Ends Autoimmune Skin Disorder Program
Benzinga · 3d ago
Roivant Sciences price target raised to $41 from $37.50 at BofA
TipRanks · 3d ago
Roivant slips as Immunovant faces trial setback for cutaneous lupus therapy
Seeking Alpha · 3d ago
Roivant announces trial of IMVT-1402 did not reach statistical significance
TipRanks · 3d ago
Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint
Benzinga · 3d ago
More
About ROIV
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Webull offers Roivant Sciences Ltd stock information, including NASDAQ: ROIV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ROIV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ROIV stock methods without spending real money on the virtual paper trading platform.